SCHEMBL24315675

SCHEMBL24315675

COC1(C(C)C)CCN(Cc2ccc(S(=O)(=O)N3CCOCC3)cc2)C1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
TSHR P16473 3/20 0.52
USP2 O75604 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPK1 P28482 3/20 0.44
POLB P06746 2/20 0.44
GAA P10253 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
CYP3A4 P08684 1/20 0.43
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27010257 0.94 ALDH1A1 (0.52) ALDH1A1TSHRUSP2KDM4EHSD17B10
SCHEMBL27010253 0.94 TSHR (0.57) ALDH1A1TSHRUSP2KDM4EHSD17B10
SCHEMBL27010323 0.92 ALDH1A1 (0.57) ALDH1A1TSHRUSP2KDM4EHSD17B10
SCHEMBL27010379 0.88 L3MBTL1 (0.48) ALDH1A1TSHRUSP2LMNASMN1; SMN2
SCHEMBL27010384 0.85 ALDH1A1 (0.56) ALDH1A1TSHRUSP2KDM4ELMNA
SCHEMBL24317829 0.84 ALDH1A1 (0.57) ALDH1A1TSHRUSP2KDM4ELMNA
SCHEMBL26620380 0.84 TSHR (0.55) ALDH1A1TSHRUSP2KDM4EHSD17B10
SCHEMBL27010251 0.83 TSHR (0.60) ALDH1A1TSHRKDM4ELMNASMN1; SMN2
SCHEMBL24315684 0.81 PTGDR2 (0.42) ALDH1A1TSHRUSP2SMN1; SMN2GAA
SCHEMBL27010252 0.81 TSHR (0.60) ALDH1A1TSHRKDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 ALDH1A1 2267/4885TSHR 2445/4885USP2 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.